KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) EBIAT: 2009-2025

Historic EBIAT for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Sep 2025 value amounting to $1.5 billion.

  • Regeneron Pharmaceuticals' EBIAT rose 8.91% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 billion, marking a year-over-year decrease of 1.64%. This contributed to the annual value of $4.4 billion for FY2024, which is 11.61% up from last year.
  • As of Q3 2025, Regeneron Pharmaceuticals' EBIAT stood at $1.5 billion, which was up 4.92% from $1.4 billion recorded in Q2 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' EBIAT peaked at $3.1 billion during Q2 2021, and registered a low of $722.0 million during Q1 2024.
  • Over the past 3 years, Regeneron Pharmaceuticals' median EBIAT value was $1.0 billion (recorded in 2023), while the average stood at $1.1 billion.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' EBIAT surged by 245.36% in 2021, and later crashed by 72.50% in 2022.
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' EBIAT stood at $2.2 billion in 2021, then tumbled by 46.29% to $1.2 billion in 2022, then declined by 3.13% to $1.2 billion in 2023, then dropped by 20.86% to $917.7 million in 2024, then rose by 8.91% to $1.5 billion in 2025.
  • Its EBIAT was $1.5 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $808.7 million in Q1 2025.